| __timestamp | Bausch Health Companies Inc. | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 246000000 | 15823000 |
| Thursday, January 1, 2015 | 582800000 | 17026000 |
| Friday, January 1, 2016 | 455000000 | 15941000 |
| Sunday, January 1, 2017 | 366000000 | 18938000 |
| Monday, January 1, 2018 | 414000000 | 58124000 |
| Tuesday, January 1, 2019 | 471000000 | 83837000 |
| Wednesday, January 1, 2020 | 452000000 | 35882000 |
| Friday, January 1, 2021 | 465000000 | 64542000 |
| Saturday, January 1, 2022 | 529000000 | 67995000 |
| Sunday, January 1, 2023 | 604000000 | 80118000 |
Cracking the code
In the ever-evolving landscape of pharmaceuticals, innovation is the lifeblood of progress. Over the past decade, CymaBay Therapeutics, Inc. and Bausch Health Companies Inc. have demonstrated contrasting approaches to research and development (R&D) spending.
From 2014 to 2023, Bausch Health's R&D expenses have surged by approximately 145%, peaking in 2023. This reflects a robust commitment to innovation, with spending consistently exceeding $400 million annually since 2015. In contrast, CymaBay Therapeutics, Inc. has shown a more modest increase of around 400% over the same period, with a notable spike in 2019.
While Bausch Health's spending dwarfs that of CymaBay, the latter's strategic investments have yielded significant growth. This comparison underscores the diverse strategies companies employ to drive innovation, each tailored to their unique market positions and goals.
Comparing Innovation Spending: Novo Nordisk A/S and CymaBay Therapeutics, Inc.
Research and Development Investment: Vertex Pharmaceuticals Incorporated vs CymaBay Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Viatris Inc. vs CymaBay Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and CymaBay Therapeutics, Inc.
Ionis Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Opthea Limited and CymaBay Therapeutics, Inc.
Research and Development Investment: Verona Pharma plc vs CymaBay Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ADMA Biologics, Inc. and Bausch Health Companies Inc.
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.
R&D Spending Showdown: CymaBay Therapeutics, Inc. vs ImmunityBio, Inc.
Research and Development: Comparing Key Metrics for CymaBay Therapeutics, Inc. and Galapagos NV